Condition: Breast Cancer · Metastatic Breast Cancer · Cancer Therapy-Related Cardiac Dysfunction · Sponsor: University Hospital, Akershus
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. Further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.
This description comes directly from the study's public registry record.
Torbjørn Omland, MD, PhD · +47 40107050 · torbjorn.omland@medisin.uio.no
Victoria Vinje, MD · +47 92033665 · victoria.vinje@ahus.no
Always discuss trial participation with your own doctor first.
| Akershus University Hospital | Lørenskog, Akershus, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05732051